CR10823A - Formulacion parenteral de anticuerpos abeta - Google Patents
Formulacion parenteral de anticuerpos abetaInfo
- Publication number
- CR10823A CR10823A CR10823A CR10823A CR10823A CR 10823 A CR10823 A CR 10823A CR 10823 A CR10823 A CR 10823A CR 10823 A CR10823 A CR 10823A CR 10823 A CR10823 A CR 10823A
- Authority
- CR
- Costa Rica
- Prior art keywords
- parenteral formulation
- abeta antibodies
- abeta
- antibodies
- parenteral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06025590 | 2006-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10823A true CR10823A (es) | 2009-08-12 |
Family
ID=39190366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10823A CR10823A (es) | 2006-12-11 | 2009-05-21 | Formulacion parenteral de anticuerpos abeta |
Country Status (21)
Country | Link |
---|---|
US (1) | US20110070225A1 (es) |
EP (1) | EP2094729A1 (es) |
JP (1) | JP2010512356A (es) |
KR (1) | KR20090104017A (es) |
CN (1) | CN101553504A (es) |
AR (1) | AR064220A1 (es) |
AU (1) | AU2007331712A1 (es) |
BR (1) | BRPI0721097A2 (es) |
CA (1) | CA2671968A1 (es) |
CL (1) | CL2007003583A1 (es) |
CR (1) | CR10823A (es) |
EC (1) | ECSP099403A (es) |
IL (1) | IL198963A0 (es) |
MA (1) | MA30975B1 (es) |
MX (1) | MX2009006199A (es) |
NO (1) | NO20092586L (es) |
PE (1) | PE20081477A1 (es) |
RU (1) | RU2009126420A (es) |
TW (1) | TW200831133A (es) |
WO (1) | WO2008071394A1 (es) |
ZA (1) | ZA200904014B (es) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
TW200530269A (en) | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
US9493569B2 (en) | 2005-03-31 | 2016-11-15 | Chugai Seiyaku Kabushiki Kaisha | Structural isomers of sc(Fv)2 |
KR101360671B1 (ko) | 2005-06-10 | 2014-02-07 | 추가이 세이야쿠 가부시키가이샤 | sc(Fv)2를 함유하는 의약조성물 |
BRPI0619249A2 (pt) | 2005-11-30 | 2011-09-20 | Abbott Lab | anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos |
CN101506236B (zh) | 2005-11-30 | 2012-12-12 | 雅培制药有限公司 | 抗淀粉样β蛋白的单克隆抗体及其用途 |
PE20100684A1 (es) * | 2005-12-12 | 2010-10-04 | Hoffmann La Roche | Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2486928A1 (en) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
CN101883790B (zh) | 2007-10-05 | 2015-09-09 | 基因技术公司 | 抗淀粉样蛋白β抗体在眼病中的用途 |
EP2993186B1 (en) | 2008-03-14 | 2019-09-04 | Biocon Limited | A monoclonal antibody and a method thereof |
KR101784231B1 (ko) * | 2008-06-20 | 2017-11-08 | 노파르티스 아게 | 응집이 감소된 면역글로불린 |
AU2009294680A1 (en) * | 2008-09-19 | 2010-03-25 | F. Hoffmann-La Roche Ag | Novel antibody formulation |
CN102271707B (zh) | 2008-10-29 | 2015-04-08 | 阿布林克斯公司 | 单域抗原结合性分子的制剂 |
WO2010056550A1 (en) | 2008-10-29 | 2010-05-20 | Wyeth Llc | Methods for purification of single domain antigen binding molecules |
KR20110086705A (ko) * | 2008-11-17 | 2011-07-29 | 제넨테크, 인크. | 생리학적 조건 하에 거대분자의 응집을 감소시키는 방법 및 제제 |
EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
WO2010069858A1 (en) * | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
WO2010100179A2 (en) * | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
CA2781467C (en) * | 2009-11-20 | 2015-10-13 | Biocon Limited | Formulations of antibody |
JP2013515754A (ja) * | 2009-12-29 | 2013-05-09 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 新規な抗体製剤 |
AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
EP3708190A1 (en) | 2010-02-26 | 2020-09-16 | Novo Nordisk A/S | Stable antibody containing compositions |
NZ602115A (en) | 2010-03-01 | 2014-12-24 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
PE20130527A1 (es) | 2010-03-03 | 2013-05-09 | Boehringer Ingelheim Int | Polipeptidos de union a a-beta biparatopicos |
MX360403B (es) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Proteinas de union a amiloide beta. |
US20130136733A1 (en) | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
RU2607368C2 (ru) | 2010-07-30 | 2017-01-10 | Ац Иммуне С.А. | Безопасные и функциональные гуманизированные антитела |
JP6147665B2 (ja) | 2010-08-14 | 2017-06-14 | アッヴィ・インコーポレイテッド | アミロイドベータ結合タンパク質 |
WO2012028683A1 (en) * | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
CN107998388B (zh) * | 2011-05-02 | 2023-07-14 | 千禧制药公司 | 抗α4β7抗体的制剂 |
WO2012151199A1 (en) | 2011-05-02 | 2012-11-08 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
EA037797B1 (ru) | 2011-10-25 | 2021-05-21 | Протена Байосайенсиз Лимитед | Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения |
RU2014140137A (ru) * | 2012-03-08 | 2016-04-27 | Ф.Хоффманн-Ля Рош Аг | Лекарственный препарат антитела к бета-амилоиду |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
JP6265970B2 (ja) * | 2012-03-26 | 2018-01-24 | サノフイ | 安定なIgG4に基づく結合剤の製剤 |
US20130281355A1 (en) | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
CA2906101A1 (en) * | 2013-03-15 | 2014-09-18 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
NZ746944A (en) | 2013-07-23 | 2021-07-30 | Biocon Ltd | Use of a cd6 binding partner and method based thereon |
EP3209682B1 (en) | 2014-10-24 | 2020-12-30 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and glp-1 receptors |
WO2016080367A1 (ja) * | 2014-11-18 | 2016-05-26 | 塩野義製薬株式会社 | 安定化されたペプチド組成物 |
CN104946616A (zh) * | 2015-05-12 | 2015-09-30 | 骏实生物科技(上海)有限公司 | 一种用于体外诊断试剂的通用固体稳定剂及其使用方法 |
AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
HRP20220304T1 (hr) | 2015-06-24 | 2022-05-13 | F. Hoffmann - La Roche Ag | Anti-transferinska receptorska protutijela s prilagođenim afinitetom |
ES2818229T3 (es) * | 2015-08-19 | 2021-04-09 | Astrazeneca Ab | Formulación anti-IFNAR1 estable |
CN108025072A (zh) * | 2015-09-22 | 2018-05-11 | 辉瑞公司 | 制备治疗用蛋白质制剂的方法和由这种方法生产的抗体制剂 |
PE20181004A1 (es) | 2015-10-02 | 2018-06-26 | Hoffmann La Roche | Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
CN106620691B (zh) * | 2015-11-04 | 2020-08-21 | 信达生物制药(苏州)有限公司 | 一种重组全人源抗ctla-4单克隆抗体制剂及其应用 |
US10525137B2 (en) | 2015-12-30 | 2020-01-07 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
CN106199007B (zh) * | 2016-08-03 | 2017-04-05 | 烟台普罗吉生物科技发展有限公司 | 蛋白保护剂 |
CA3039855A1 (en) | 2016-10-21 | 2018-04-26 | Biocon Limited | A monoclonal antibody and a method of use for the treatment of lupus |
CN106913869B (zh) * | 2017-03-17 | 2020-07-28 | 信达生物制药(苏州)有限公司 | 一种抗ctla-4单克隆抗体制剂及其应用 |
EP3606964A4 (en) | 2017-04-03 | 2020-12-09 | Immunomedics, Inc. | SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY |
EA202090555A1 (ru) * | 2017-08-22 | 2020-06-08 | Байоджен Ма Инк. | Фармацевтические композиции, содержащие антитела к бета-амилоиду |
CN108373494A (zh) * | 2018-02-27 | 2018-08-07 | 武汉伊艾博科技有限公司 | 一种防止重组蛋白质降解的保护技术 |
MX2021009851A (es) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos. |
CN112618482A (zh) * | 2019-09-24 | 2021-04-09 | 江苏恒瑞医药股份有限公司 | 新型蛋白制剂 |
CN112741804A (zh) * | 2019-10-31 | 2021-05-04 | 上海君实生物医药科技股份有限公司 | 含有抗pd-l1抗体的稳定制剂 |
CN113116812A (zh) * | 2019-12-30 | 2021-07-16 | 百奥泰生物制药股份有限公司 | 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用 |
EP4221750A1 (en) * | 2020-09-30 | 2023-08-09 | Merck Sharp & Dohme LLC | Binding proteins and antigen binding fragments thereof that bind abeta |
CN117088974B (zh) * | 2023-08-14 | 2024-02-13 | 武汉健昊生物科技有限公司 | 一种抗体保存液 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
JP4317010B2 (ja) * | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ,インコーポレイティド | IgG抗体の安定な凍結乾燥医薬製剤 |
AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
RU2332986C2 (ru) * | 2003-04-04 | 2008-09-10 | Дженентек, Инк. | Высококонцентрированные композиции антител и белков |
GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
AR052469A1 (es) * | 2005-01-28 | 2007-03-21 | Wyeth Corp | Formulaciones liquidas estabilizadas de polipeptido |
PE20100684A1 (es) * | 2005-12-12 | 2010-10-04 | Hoffmann La Roche | Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh |
KR20080104160A (ko) * | 2006-03-28 | 2008-12-01 | 에프. 호프만-라 로슈 아게 | 항-igf-1r 인간 단일클론 항체 제형 |
-
2007
- 2007-12-11 CA CA002671968A patent/CA2671968A1/en not_active Abandoned
- 2007-12-11 BR BRPI0721097-3A patent/BRPI0721097A2/pt not_active IP Right Cessation
- 2007-12-11 US US12/448,190 patent/US20110070225A1/en not_active Abandoned
- 2007-12-11 TW TW096147285A patent/TW200831133A/zh unknown
- 2007-12-11 WO PCT/EP2007/010825 patent/WO2008071394A1/en active Application Filing
- 2007-12-11 EP EP07856573A patent/EP2094729A1/en not_active Withdrawn
- 2007-12-11 PE PE2007001764A patent/PE20081477A1/es not_active Application Discontinuation
- 2007-12-11 KR KR1020097013954A patent/KR20090104017A/ko not_active Application Discontinuation
- 2007-12-11 RU RU2009126420/10A patent/RU2009126420A/ru not_active Application Discontinuation
- 2007-12-11 MX MX2009006199A patent/MX2009006199A/es not_active Application Discontinuation
- 2007-12-11 AR ARP070105523A patent/AR064220A1/es unknown
- 2007-12-11 AU AU2007331712A patent/AU2007331712A1/en not_active Abandoned
- 2007-12-11 CN CNA2007800455861A patent/CN101553504A/zh active Pending
- 2007-12-11 JP JP2009540650A patent/JP2010512356A/ja not_active Withdrawn
- 2007-12-11 CL CL200703583A patent/CL2007003583A1/es unknown
-
2009
- 2009-05-21 CR CR10823A patent/CR10823A/es not_active Application Discontinuation
- 2009-05-26 IL IL198963A patent/IL198963A0/en unknown
- 2009-06-08 MA MA31963A patent/MA30975B1/fr unknown
- 2009-06-09 ZA ZA200904014A patent/ZA200904014B/xx unknown
- 2009-06-11 EC EC2009009403A patent/ECSP099403A/es unknown
- 2009-07-07 NO NO20092586A patent/NO20092586L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20090104017A (ko) | 2009-10-05 |
PE20081477A1 (es) | 2008-10-18 |
RU2009126420A (ru) | 2011-01-20 |
NO20092586L (no) | 2009-07-17 |
TW200831133A (en) | 2008-08-01 |
AU2007331712A1 (en) | 2008-06-19 |
WO2008071394A1 (en) | 2008-06-19 |
JP2010512356A (ja) | 2010-04-22 |
ZA200904014B (en) | 2010-04-28 |
MA30975B1 (fr) | 2009-12-01 |
US20110070225A1 (en) | 2011-03-24 |
AR064220A1 (es) | 2009-03-18 |
CA2671968A1 (en) | 2008-06-19 |
ECSP099403A (es) | 2009-07-31 |
IL198963A0 (en) | 2011-08-01 |
CL2007003583A1 (es) | 2008-07-18 |
CN101553504A (zh) | 2009-10-07 |
EP2094729A1 (en) | 2009-09-02 |
MX2009006199A (es) | 2009-06-22 |
BRPI0721097A2 (pt) | 2014-07-01 |
AU2007331712A2 (en) | 2009-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10823A (es) | Formulacion parenteral de anticuerpos abeta | |
CY2019004I2 (el) | Τροποποιημενα αντισωματα αντι-ιl-23ρ19 | |
SMT201600222B (it) | Formulazione di anticorpi | |
DOP2007000084A (es) | Derivados de dihidropirazolopirimidinona | |
BRPI0820819A2 (pt) | Formulação de anticorpos | |
BRPI0820407A2 (pt) | Uso de anticorpos anti-cd40 | |
NO344963B1 (no) | Humanisert antistoff | |
DK2066695T3 (da) | Anti-myostatin-antistoffer | |
BRPI0819165A2 (pt) | Anticorpos anti-vegf | |
NO347644B1 (no) | Polymorfer | |
CR10841A (es) | Imidazotriazinas imidazopirimidinas inhibidores de cinasa | |
BRPI0814003A2 (pt) | Formulações de anticorpo | |
DK1981859T3 (da) | Fremstilling af delmopinol | |
BRPI0814252A2 (pt) | Formulações de anticorpo | |
CR10562A (es) | Nuevos derivados de piridazina | |
CY2013046I2 (el) | Καινοτομος χρηση των αντισωματων αντι il-1bhta | |
DK2034830T3 (da) | Anti-vla-1-antistof til behandling af slagtilfælde | |
BRPI0817427A2 (pt) | Anticorpo anti-bst2 | |
CR10809A (es) | Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona | |
FR2902426B1 (fr) | Derives de cinnamoyl-piperazine | |
FI20065834A0 (fi) | Iskulaite | |
FI20065478A0 (fi) | Bioanturi | |
DE502007001783D1 (de) | Bauteilhalterung | |
FR2902427B1 (fr) | Derives de phenylpentadienoyle | |
DK1999128T3 (da) | Tetomilast-polymorf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |